Private Label Tranexamic Acid SPF 50 Sunscreen Manufacturer Low MOQ

What claims can I make on a private label tranexamic acid SPF 50 sunscreen label?

By Blake Mereby · Last reviewed October 5, 2026

Claim strategy for a tranexamic acid SPF 50 sunscreen is one of the most nuanced areas of this product type, because you're operating at the intersection of drug labeling law (for the sunscreen component) and cosmetic marketing (for the brightening active). Getting it wrong can result in FDA warning letters, EU regulatory non-compliance, or consumer advertising challenges.

In the United States, the Drug Facts panel is non-negotiable. It must follow the exact format and content requirements of 21 CFR 201.66. The active ingredient section lists only the FDA-approved UV filters and their concentrations. Tranexamic acid does not appear here. The purpose claim on the Drug Facts panel must state something like 'Sunscreen' or 'Helps prevent sunburn.' Disease claims (melasma treatment, for example) are not permitted on an OTC sunscreen label without an NDA. Your front-of-pack and marketing copy can reference brightening, dark spot reduction, and hyperpigmentation as cosmetic benefits, but these must be structured as cosmetic (appearance) claims, not drug claims. Do not use language like 'treats melasma,' 'reduces discoloration caused by hormonal changes,' or anything that implies a medical diagnosis or treatment.

Permitted front-of-pack claims in the US context include: 'Visibly reduces dark spots,' 'Brightening SPF 50,' 'Broad spectrum SPF 50,' and 'Formulated with tranexamic acid.' These are appearance claims that do not trigger drug claim classification. Pair these with 'Helps prevent sunburn' and 'If used as directed with other sun protection measures, decreases the risk of skin cancer and early skin aging' — which are the only OTC-permitted disease-reduction claims for sunscreen.

In the European Union, the EU Cosmetics Regulation Annex III limits tranexamic acid to 2% and classifies it as a cosmetic ingredient. The SPF claim must be supported by an in-vitro test result per COLIPA/ISO guidelines. EU sunscreen claims must follow the Commission Recommendation of 2006 on SPF labeling, which means SPF 50 falls into the 'Very High Protection' category and must be labeled accordingly. REACH considerations apply to ingredient transparency in the supply chain, but do not typically affect finished product labeling directly.

In Canada, if the product is classified as a Natural Health Product or drug under Health Canada, SPF and brightening claims both fall under tighter scrutiny. Claims like 'reduces dark spots' may require clinical evidence to be submitted as part of the product license application.

Document every claim with the substantiation it relies on before launch. For tranexamic acid's brightening efficacy, published peer-reviewed studies at 2–3% concentrations in comparable emulsion systems can serve as literature substantiation for cosmetic claims in many markets. For the SPF 50 claim, only your specific product's SPF test result counts.

Ingredients in this answer: Tranexamic Acid

Read the full guide on Private Label Tranexamic Acid SPF 50 Sunscreen Manufacturer Low MOQ →

More about Private Label Tranexamic Acid SPF 50 Sunscreen Manufacturer Low MOQ

Tell us about your product

Tell us what you're selling and where. You can hire a vetted cosmetic chemist on AJ Cosmo Labs to review your formula and labeling. Starting is free.

Free to start · no credit card · continue in your browser or the iPhone app.

Have a product idea?

Connect with vetted cosmetic chemists and custom labs on AJ Cosmo Labs.

Get on the App Store Open the web app